Chemotherapy use and patient treatment preferences in advanced colorectal cancer: A prospective cohort study

Cancer

Volumn 119, Issue 4, 2013, Pages 854-862

  Zafar, S Yousuf ^a,b   Malin, Jennifer L ^c,d   Grambow, Steven C ^b,e   Abbott, David H ^b   Kolimaga, Jane T ^b,e   Zullig, Leah L ^b,f   Weeks, Jane C ^g   Ayanian, John Z ^h   Kahn, Katherine L ^i,j   Ganz, Patricia A ^j   Catalano, Paul J ^g,k   West, Dee W ^l,m   Provenzale, Dawn ^b  

^a DUKE CANCER INSTITUTE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f IL   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ RAND CORPORATION   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^l CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^m STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

cohort studies; colorectal cancer; decision making; patient preference; quality of health care

Indexed keywords

BIOLOGICAL PRODUCT; CAPECITABINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER THERAPY; COHORT ANALYSIS; COLORECTAL CANCER; COMORBIDITY; FEMALE; HEALTH BELIEF; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; ONCOLOGIST; PATIENT INFORMATION; PATIENT PREFERENCE; PHYSICIAN; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COLORECTAL NEOPLASMS; DATA COLLECTION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MEDICAL ONCOLOGY; PALLIATIVE CARE; PATIENT PREFERENCE; PROSPECTIVE STUDIES;

EID: 84873413388     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27815     Document Type: Article

References (33)

1. Whelan T, Levine M, Willan A, et al. Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery. JAMA. 2004; 292: 435-441.
2. Whelan T, Sawka C, Levine M, et al. Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J Natl Cancer Inst. 2003; 95: 581-587.
3. Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM,. Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care. 2007; 45: 431-439.
4. Meyerhardt JA, Li L, Sanoff HK, Carpenter W, Schrag D,. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol. 2012; 30: 608-615.
5. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ,. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol. 2008; 26: 3860-3866.
6. de Haes H, Koedoot N,. Patient centered decision making in palliative cancer treatment: a world of paradoxes. Patient Educ Couns. 2003; 50: 43-49.
7. Keating NL, Beth Landrum M, Arora NK, et al. Cancer patients' roles in treatment decisions: do characteristics of the decision influence roles? J Clin Oncol. 2010; 28: 4364-4370.
8. Elkin EB, Kim SHM, Casper ES, Kissane DW, Schrag D,. Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions. J Clin Oncol. 2007; 25: 5275-5280.
9. Ayanian JZ, Chrischilles EA, Wallace RB, et al. Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol. 2004; 22: 2992-2996.
10. Kahn KL, Adams JL, Weeks JC, et al. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA. 2010; 303: 1037-1045.
11. Malin J, Ko C, Ayanian J, et al. Understanding cancer patients' experience and outcomes: development and pilot study of the Cancer Care Outcomes Research and Surveillance patient survey. Supp Care Cancer. 2006; 14: 837-848.
12. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr,. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004; 291: 2441-2447.
13. Vittinghoff E, McCulloch CE,. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007; 165: 710-718.
14. He Y, Zaslavsky AM, Harrington DP, Catalano PJ, Landrum MB,. Imputation in a Multiformat and Multiwave Survey of Cancer Care. Proceedings in Health Policy Statistics. Alexandria, VA: American Statistical Association; 2007.
15. Little RJ, Rubin DB,. Statistical Analysis with Missing Data. 2nd ed. Hoboken, NJ: Wiley-Interscience; 2002.
16. Zafar SY, Alexander SC, Weinfurt KP, Schulman KA, Abernethy AP,. Decision making and quality of life in the treatment of cancer: a review. Support Care Cancer. 2009; 17: 117-127.
17. Molenaar S, Oort F, Sprangers M, et al. Predictors of patients' choices for breast-conserving therapy or mastectomy: a prospective study. Br J Cancer. 2004; 90: 2123-2130.
18. Clark HD, O'Connor AM, Graham ID, Wells GA,. What factors are associated with a woman's decision to take hormone replacement therapy? Evaluated in the context of a decision aid. Health Expect. 2003; 6: 110-117.
19. Hodgson DC, Fuchs CS, Ayanian JZ,. Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer. J Natl Cancer Inst. 2001; 93: 501-515.
20. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF,. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002; 20: 1192-1202.
21. Keating NL, Landrum MB, Klabunde CN, et al. Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? J Clin Oncol. 2008; 26: 2532-2537.
22. Schrag D, Cramer LD, Bach PB, Begg CB,. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001; 93: 850-857.
23. Cronin DP, Harlan LC, Potosky AL, Clegg LX, Stevens JL, Mooney MM,. Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol. 2006; 101: 2308-2318.
24. Jessup JM, Stewart A, Greene FL, Minsky BD,. Adjuvant chemotherapy for stage III colon cancer. JAMA. 2005; 294: 2703-2711.
25. Gross C, McAvay G, Guo Z, Tinetti M,. The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer. 2007; 109: 2410-2419.
26. Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003; 21: 1293-1300.
27. Neo EL, Beeke C, Price T, et al. South Australian clinical registry for metastatic colorectal cancer. ANZ J Surg. 2011; 81: 352-357.
28. Price T, Pittman K, Patterson W, et al. Management and survival trends in advanced colorectal cancer. Clin Oncol (R Coll Radiol). 2008; 20: 626-630.
29. van der Pool AE, Damhuis RA, Ijzermans JN, et al. Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis. 2012; 14: 56-61.
30. Ksienski D, Woods R, Speers C, Kennecke H,. Patterns of referral and resection among patients with liver-only metastatic colorectal cancer (MCRC). Ann Surg Oncol. 2010; 17: 3085-3093.
31. Renouf D, Kennecke H, Gill S,. Trends in chemotherapy utilization for colorectal cancer. Clin Colorectal Cancer. 2008; 7: 386-389.
32. Stiggelbout AM, de Haes JCJM,. Patient preference for cancer therapy: an overview of measurement approaches. J Clin Oncol. 2001; 19: 220-230.
33. Catalano PJ, Ayanian JZ, Weeks JC, et al. Representativeness of participants in the Cancer Care Outcomes Research and Surveillance Consortium relative to the Surveillance, Epidemiology, and End Results Program [published online a head of print March 7, 2012]. Med Care. 2012.